Literature DB >> 26088953

Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy.

D H Wiseman1, E A Struys2, D P Wilks3, C I Clark4, M W Dennis5, E E W Jansen2, G S Salomons2, T C P Somervaille1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26088953     DOI： 10.1038/leu.2015.151

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Quantification of rare NPM1 mutation subtypes by digital PCR.

Authors:  Ulrike Bacher; Frank Dicker; Claudia Haferlach; Tamara Alpermann; Dominic Rose; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Journal:  Br J Haematol       Date:  2014-07-18       Impact factor: 6.998

2.  Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.

Authors:  Daniel H Wiseman; Helen F Small; Deepti P Wilks; Ian D Waddell; Michael W Dennis; Donald J Ogilvie; Tim C P Somervaille
Journal:  Br J Haematol       Date:  2014-03-10       Impact factor: 6.998

Review 3.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

4.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

5.  Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.

Authors:  V G Oehler; J Qin; R Ramakrishnan; G Facer; S Ananthnarayan; C Cummings; M Deininger; N Shah; F McCormick; S Willis; A Daridon; M Unger; J P Radich
Journal:  Leukemia       Date:  2008-07-10       Impact factor: 11.528

6.  Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride.

Authors:  Eduard A Struys; Erwin E W Jansen; Nanda M Verhoeven; Cornelis Jakobs
Journal:  Clin Chem       Date:  2004-05-27       Impact factor: 8.327

7.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

8.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

Authors:  Courtney D DiNardo; Kathleen J Propert; Alison W Loren; Elisabeth Paietta; Zhuoxin Sun; Ross L Levine; Kimberly S Straley; Katharine Yen; Jay P Patel; Samuel Agresta; Omar Abdel-Wahab; Alexander E Perl; Mark R Litzow; Jacob M Rowe; Hillard M Lazarus; Hugo F Fernandez; David J Margolis; Martin S Tallman; Selina M Luger; Martin Carroll
Journal:  Blood       Date:  2013-05-02       Impact factor: 25.476

9.  Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Authors:  Maxime Janin; Elena Mylonas; Véronique Saada; Jean-Baptiste Micol; Aline Renneville; Cyril Quivoron; Serge Koscielny; Laurianne Scourzic; Sébastien Forget; Cécile Pautas; Denis Caillot; Claude Preudhomme; Hervé Dombret; Céline Berthon; Robert Barouki; Daniel Rabier; Nathalie Auger; Frank Griscelli; Elisabeth Chachaty; Edwige Leclercq; Marie-Hélène Courtier; Annelise Bennaceur-Griscelli; Eric Solary; Olivier Adrien Bernard; Virginie Penard-Lacronique; Chris Ottolenghi; Stéphane de Botton
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 50.717

10.  Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.

Authors:  Amir T Fathi; Hossein Sadrzadeh; Darrell R Borger; Karen K Ballen; Philip C Amrein; Eyal C Attar; Julia Foster; Meghan Burke; Hector U Lopez; Christina R Matulis; Katherine M Edmonds; A John Iafrate; Kimberly S Straley; Katharine E Yen; Samuel Agresta; David P Schenkein; Cedric Hill; Ashkan Emadi; Donna S Neuberg; Richard M Stone; Yi-Bin Chen
Journal:  Blood       Date:  2012-10-16       Impact factor: 25.476
View more
  3 in total

Review 1.  Methods of Detection of Measurable Residual Disease in AML.

Authors:  Yi Zhou; Brent L Wood
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

2.  A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.

Authors:  Mohammed Khurshed; Remco J Molenaar; Myra E van Linde; Ron A Mathôt; Eduard A Struys; Tom van Wezel; Cornelis J F van Noorden; Heinz-Josef Klümpen; Judith V M G Bovée; Johanna W Wilmink
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

3.  Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia.

Authors:  D H Wiseman; E L Williams; D P Wilks; H Sun Leong; T D D Somerville; M W Dennis; E A Struys; A Bakkali; G S Salomons; T C P Somervaille
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 12.883
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.